For example, Ding W et al. pointed out that FGF9, as part of the antiapoptotic pathway involved in circLRP62-2 and hnRNPM, can enhance the survival of cardiomyocytes under hypoxic conditions and provide a potential therapeutic target for coronary heart disease and ischemic myocardial injury [19]. The gene discussed is FGF9; the disease is coronary artery disorder.